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ABSTRACT
Objective: Because of the lack of head-to-head trials,
the aim was to indirectly compare sodium glucose
transporter-2 (SGLT-2) inhibitors in the treatment of
type 2 diabetes.
Design: Systematic review and network meta-analysis.
Data sources: MEDLINE and EMBASE were searched
from January 2005 to January 2015.
Eligibility criteria: Randomised controlled trials
assessing the efficacy of SGLT-2 inhibitors in patients
with type 2 diabetes inadequately controlled with diet
and exercise alone or metformin monotherapy.
Minimum duration 24 weeks. Indirect comparison was
undertaken using Bayesian methods.
Results: In monotherapy, a greater proportion of
patients achieved a glycated haemoglobin (HbA1c)
level of <7% on canagliflozin 300 mg than on
canagliflozin 100 mg (risk ratio (RR) 0.72%, 95%
credible intervals (CrI) 0.59% to 0.87%) and
dapagliflozin 10 mg (RR 0.63, 95% CrI 0.48 to 0.85)
but there were no significant differences compared
with either dose of empagliflozin. In monotherapy,
canagliflozin 300 mg reduced HbA1c more than other
SGLT-2 inhibitors (mean difference ranged from 0.20%
to 0.64%). There were no significant differences in
weight reduction. All the flozins reduced systolic blood
pressure (SBP) more than placebo, ranging from a
reduction of 6 mm Hg with canagliflozin 300–
2.6 mm Hg with empagliflozin 10 mg. In dual therapy
with metformin, all flozins were more effective than
placebo for achieving HbA1c <7%, and reducing
HbA1c, weight and SBP. The proportions achieving
HbA1c level of <7% were mostly similar. Canagliflozin
300 mg reduced HbA1c more than the other drugs but
this just reached statistical significance only against
canagliflozin 100 mg (MD 0.15, CrI 0.04 to 0.26).
Conclusions: There were few differences among the
SGLT-2 inhibitors, but in monotherapy, the glucose-
lowering effect of canagliflozin 300 mg is slightly
greater than most other SGLT-2 inhibitors.
INTRODUCTION
The newest class of drugs for type 2 diabetes
are the sodium glucose co-transporter 2
receptor (SGLT-2) inhibitors. These reduce
the reabsorption of renal-ﬁltered glucose
back into the bloodstream, thereby leading
to loss of glucose in the urine. In the UK,
the ﬁrst three drugs in this class to reach the
market, dapagliﬂozin, canagliﬂozin and
empagliﬂozin, have been approved by the
National Institute for Health and Care
Excellence (NICE).1–3
In addition to the SGLT-2 transport system
in the kidney, there is also a related transport
system in the gut, SGLT-1. Most SGLT-2 inhi-
bitors have no signiﬁcant effect of SGLT-1,
but one of the class, canagliﬂozin, does
affect SGLT-1, and it has been suggested by
Polidori et al4 that canagliﬂozin may reduce
blood glucose by a dual action in both gut
and kidney. However, that suggestion fol-
lowed a very short-term study of canagliﬂozin
in healthy individuals, and the gut effect was
seen only with higher doses (>200 mg).
A second study by Polidori and colleagues
from Janssen Research and Development
looked at the SGLT-1 effect in people with
type 2 diabetes5 and found that canagliﬂozin
300 mg, but not 150 mg, reduced postpran-
dial plasma glucose, by about 0.5 mmol/L
(from graph) for about 2 h after
Strengths and limitations of this study
▪ In the absence of head-to-head comparisons of
different sodium glucose transporter-2 inhibitors,
a Bayesian network meta-analysis was used to
compare the efficacy of the drugs.
▪ Studies were identified by a systematic search,
and data abstraction and quality assessment of
the studies were done independently by two
authors.
▪ The study also includes the newer drugs in this
class namely luseogliflozin, ipragliflozin and
tofogliflozin.
▪ Safety data were not compared. The trials were
for a maximum of 26 weeks duration.
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administration, since it depends on an intestinal drug
action not a systemic one. Would a change of that mag-
nitude be enough to make a clinically meaningful differ-
ence in glycated haemoglobin (HbA1c), experienced
once a day?
If the SGLT-1 effect is clinically signiﬁcant in people
with type 2 diabetes, then one might expect canagliﬂo-
zin 300 mg to be more potent in reducing HbA1c levels
than other SGLT-2 inhibitors without the SGLT-1 effect.
The usual starting dose of canagliﬂozin is 100 mg once
daily.
In the absence of head-to-head trials, the relative
potencies can only be assessed by an indirect compari-
son by a network meta-analysis (NMA). We have there-
fore carried out two NMAs, one of ﬁve drugs in
monotherapy and the other of four drugs in dual
therapy with metformin. The aim was to determine
whether the glucose-lowering effect of canagliﬂozin
would be greater than that of other ﬂozins without the
SGLT-1 effect. Secondary aims were to compare effects
on weight loss and blood pressure, and on proportions
achieving HbA1c targets.
METHODS
Information sources and search strategy
A systematic search was undertaken to identify all the
relevant studies. The searches were carried out in
MEDLINE, MEDLINE In-process and EMBASE from
January 2005 to September 2014 using search strategies
given in online supplementary appendix S1. The search
strategy was modiﬁed for other databases. The searches
were updated in January 2015 and no new studies were
found to be relevant. The reference lists of all the
included studies were also checked for possible
inclusions.
Study selection
Abstracts retrieved by the searches were screened for
inclusion or exclusion. The studies were included if they
met the following criteria: randomised controlled trial
(RCT) assessing the efﬁcacy of any SGLT-2 inhibitors in
monotherapy in patients with type 2 diabetes inad-
equately controlled with diet and exercise, and in dual
therapy in patients with inadequate control on metfor-
min monotherapy. We compared the efﬁcacies of only
licensed doses, and in the data extraction tables, details
of arms with other doses are omitted. Minimum dur-
ation was 24 weeks. The included studies should have
reported either proportion of patients achieving an
HbA1c target of <7.0% or mean change in HbA1c from
baseline to 24 weeks. We also sought changes in body
weight and systolic blood pressure (SBP) from baseline
to 24 weeks.
Risk of bias assessment
The quality of studies was assessed using the Cochrane
Collaboration’s tool for assessing risk of bias.6 The items
assessed were (1) sequence generation, (2) allocation
concealment, (3) blinding of outcome assessor, (4)
incomplete outcome data and (5) selective outcome
reporting. They were graded as unclear, high or low risk
of bias.
Study selection and data abstraction
The studies were screened for inclusion and exclusion
by one author and checked by a second. Any disagree-
ments were resolved through discussion. There was no
need for a third reviewer to resolve any disagreements
regarding inclusion or exclusion. Data extraction forms
were completed by one author and checked by a second
author. Similarly, quality assessment was done by one
author and checked by a second.
Summary measures
The proportion of patients achieving an HbA1c level
target of <7.0% at 24 weeks was summarised as risk ratio
(RR). The treatment effects of continuous outcomes,
that is, mean change in HbA1c, body weight or SBP
from baseline to 24 weeks were summarised as weighted
mean difference.
Data synthesis and model implementation
The treatment effects were assessed using a Bayesian
approach to provide probability distributions for treat-
ment effect parameters, with 95% credible intervals
(CrIs) instead of 95% CI.
A Bayesian NMA method was used to analyse all the
data, preserving randomised treatment effects within
trials and accounting for correlation between compari-
sons with three arms. The freely available software,
WinBUGS V.1.4.3, was used. The statistical heterogeneity
in treatment effect estimates was estimated using
between-study variance (ie, square root of the SD of
underlying effects across trials) with 95% CrI.7 Since our
NMA included different trials comparing different
SGLT-2 inhibitors, the distribution of treatment effect
modiﬁers cannot only vary across trials for a particular
comparison (as with standard pairwise meta-analysis,
causing heterogeneity), but also between comparisons
(causing inconsistency). If there is an imbalance in the
distribution of treatment effect modiﬁers between differ-
ent types of direct comparisons, the related indirect
comparisons will be biased.8 To estimate inconsistency in
the networks of evidence, we calculated the difference
between indirect and direct estimates whenever indirect
estimates could be constructed with a single common
comparator.9 Inconsistency was deﬁned as disagreement
between direct and indirect evidence with a 95% CrI
excluding 0 for MD and 1 for RR.10 The model conver-
gence was assessed using trace plots and the
Brooks-Gelman-Rubin statistic. The analysis was under-
taken using two Markov chains, which was ran simultan-
eously. The model was found to be converging
adequately after 20 000 samples for both chains. We ran
the model further using 70 000 samples and the results
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presented in the paper are based on these samples as we
discarded the ﬁrst 20 000 samples. The probability of a
treatment being the most effective (ﬁrst best), the
second best, and so on was also calculated. The results
have been presented graphically with median ranks.
Both ﬁxed-effect and random-effect models were
used. The Bayesian Deviation Information Criterion
(DIC) was used to compare the two models to see which
was appropriate to compare treatment effects. The DIC
measures the ﬁt of the model while penalising it for the
number of effective parameters. The model with the
lowest DIC value was considered as the most appropriate
NMA model. Based on DIC values obtained from the
two models and also because of small number of studies
available for the NMA, a ﬁxed-effect model was chosen.
Owing to small number of studies, it would have been
difﬁcult to estimate between-studies variance if a
random-effect model was implemented.
We excluded the Bolinder 2012 trial11 of dapagliﬂozin
because it recruited patients with very good baseline
HbA1c (mean 7.2%) who would have less to gain. The
primary outcome of the study was body composition and
HbA1c was an exploratory variable. The low baseline
HbA1c meant that the reduction in HbA1c was much
smaller that in other trials, creating heterogeneity.
However details are reported in tables and the Bolinder
study was included in a sensitivity analysis.
The Henry 2012 trial12 was unusual in that patients on
no drug therapy were randomised straight to dual
therapy with dapagliﬂozin and metformin (vs placebo
and metformin) without trying monotherapy ﬁrst. It is
also included in a sensitivity analysis.
We also used the ipragliﬂozin trial by Kashiwagi et al24
only in sensitivity analysis because it had unusual fea-
tures—an adjusted difference in HbA1c of 1.3%, which
was made up of a reduction of 0.87% on ipragliﬂozin
and a rise of 0.38% on placebo, despite weight loss on
placebo. More of the placebo group (52%) had by
chance had prior treatment with other glucose-lowering
drugs than in the ipragliﬂozin arm (35%, p=0.045). No
patients in the placebo group achieved HbA1c <7.0%, so
in order to run the model we used 0.5% as achieving
that.
We used a software called DigitizeIt to calculate SD
from a published ﬁgure for an outcome mean change in
HbA1c for a study13 assessing efﬁcacy of canagliﬂozin in
patients inadequately controlled with diet and exercise.
RESULTS
Study selection and characteristics
A total of 535 abstracts were retrieved from the searches
(ﬁgure 1). After removing 73 duplicate articles, there
were 462 articles left for title and abstract screening. A
Figure 1 Study selection flow
diagram.
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total of 417 articles were excluded on the basis of title
and abstracts. Forty-ﬁve articles were included for full-
text screening. Thirteen trials12–24 met all the inclusion
criteria and were included for the analysis. Table 1 gives
characteristics of all the included studies. We have sum-
marised baseline characteristics and results obtained
in trials in tables 2 and 3. We included six
trials11 12 14 15 17 18 of dapagliﬂozin, three trials13 19 22 of
canagliﬂozin, two trials of empagliﬂozin16 20 one each of
luseogliﬂozin,21 ipragliﬂozin24 and tofogliﬂozin.23
Eight trials13 15 17 18 20–23 compared the efﬁcacy of
SGLT-2 inhibitors in monotherapy with placebo in
patients inadequately controlled with diet and exercise.
Six studies11 12 14 16 19 24 compared ﬂozins with placebo
in dual therapy in patients failing to achieve glycaemic
control on metformin alone.
Not all studies reported all the outcomes. Data on
mean change in HbA1c were reported by all studies. Six
monotherapy studies13 15 17 18 20 22 reported the propor-
tion achieving HbA1c of <7.0% as did ﬁve dual therapy
studies.12 14 16 19 24 For mean change in weight,
seven15 17 18 20–23 monotherapy and ﬁve12 14 16 19 24 dual
therapy studies provided adequate information on efﬁ-
cacy of SGLT-2 inhibitors. For mean change in SBP, ﬁve
monotherapy studies13 15 20 22 23 and three dual therapy
studies16 19 24 reported sufﬁcient data. Stenlof et al13 did
not report weight SDs for the two doses of canagliﬂozin,
so this study could not be included. The weight data for
canagliﬂozin 100 mg come from Inagaki 2014 where the
100 and 200 mg doses of canagliﬂozin were used. We
excluded the 200 mg dose since this is not a standard
dose.
The networks comparing different SGLT-2 inhibitors
for proportion of patients achieving HbA1c level of <7%
in monotherapy and dual therapy are shown in ﬁgures 2
and 3.
As aforementioned, for other outcomes, some SGLT-2
inhibitors could not be included in the analysis due to
inadequate information.
Risk of bias of included trials
Most of the included studies were high in quality, with
low risk of bias. There were some studies where risk of
bias could not be judged due to inadequate information.
In this case, the risk of bias item was judged as unclear.
Details of risk of bias are shown in ﬁgure 4. All the
studies were funded by pharmaceutical companies.
Monotherapy
All SGLT-2 inhibitors were all signiﬁcantly more effective
than placebo for increasing proportion of patients
achieving HbA1c <7% (ﬁgure 5), reducing the mean
change in HbA1c (%) from baseline (ﬁgure 6), and
reducing mean weight from baseline (ﬁgure 7). All
SGLT-2 inhibitors reduced SBP compared with placebo,
but this failed to reach statistical signiﬁcance for dapagli-
ﬂozin 10 mg, tofogliﬂozin 10 and 40 mg because of wide
CIs (ﬁgure 8).
Using canagliﬂozin 300 mg as the baseline, patients
on canagliﬂozin 100 mg (RR=0.72, 95% CrI 0.59 to
0.87) and dapagliﬂozin 10 mg (RR=0.63, 95% CrI 0.48
to 0.85) were 28% and 37% less likely to have achieved
HbA1c <7% compared with those on canagliﬂozin
300 mg (ﬁgure 5). The proportions of patients achieving
HbA1c <7% were similar among empagliﬂozin 10 mg,
canagliﬂozin 100 mg and dapagliﬂozin 10 mg.
Canagliﬂozin 300 mg gave the largest reduction in
HbA1c (−1.23%) compared with placebo. Compared
with the other ﬂozins, some differences appeared not
only statistically signiﬁcant but also clinically meaningful:
canagliﬂozin 100 mg MD from canagliﬂozin 300 mg=0.20
(95% CrI 0.05 to 0.36); empagliﬂozin 25 mg (MD 0.37,
95% CrI 0.16 to 0.58); tofogliﬂozin 40 mg (MD 0.39, 95%
CrI 0.12 to 0.66); luseogliﬂozin 2.5 mg (MD=0.47, 95%
CrI 0.19 to 0.74); tofogliﬂozin 10 mg (MD 0.46, 95% CrI
0.19 to 0.73); empagliﬂozin 10 mg (0.49, 95% CrI 0.29 to
0.69); and dapagliﬂozin 10 mg (MD=0.64, 95% CrI 0.45
to 0.83; ﬁgure 6).
Canagliﬂozin 100 mg led to greater weight reduction
than the other ﬂozins; this reaching statistical signiﬁ-
cance was compared with empagliﬂozin 25 mg (MD 0.85,
95% CrI 0.37 to 1.33); empagliﬂozin 10 mg (MD 1.07,
95% CrI 0.59 to 1.56); tofogliﬂozin 10 mg (MD 1.13, 95%
CrI 0.45 to 1.80); luseogliﬂozin 2.5 mg (MD 1.20, 95%
CrI 0.63 to 1.77); and dapagliﬂozin 10 mg (MD 1.37,
95% CrI 0.92 to 1.83; ﬁgure 7).
SBP was reduced by all the ﬂozins relative to placebo,
with reductions ranging from 6.1 mm Hg for canagliﬂo-
zin 300 mg to 2.6 mm Hg for empagliﬂozin 10 mg,
though (ﬁgure 8) in some cases CIs were wide and the
reductions were not statistically signiﬁcant. Among the
ﬂozins, only empagliﬂozin 10 mg gave a difference that
was statistically signiﬁcant against canagliﬂozin (ﬁgure 8;
300 mg: MD 3.55, 95% CrI 0.60 to 6.44; 100 mg: MD
2.56, 95% CrI 0.30 to 4.75).
For some comparisons, between-study variance was
small suggesting no heterogeneity; however, the CrIs
were wide which reﬂects the small number of studies
available for pairwise comparisons. Analyses based on
direct versus indirect comparisons showed no evidence
of inconsistency between direct and indirect evidence in
the network for all outcomes.
Dual therapy
For dual therapy, we undertook sensitivity analyses by
including Kashiwagi et al24 (ipragliﬂozin), Henry et al12
(dapagliﬂozin) and Bolinder et al11 (dapagliﬂozin). Data
for all the outcomes were not available from these
studies. Therefore, a sensitivity analysis including the
ﬁrst two studies was undertaken for the proportions of
patients achieving HbA1c level of <7%, mean change in
HbA1c and mean change in weight. Bolinder et al11
study was included in the sensitivity analysis of mean
change in HbA1c and weight. Kashiwagi et al24 was also
included for sensitivity analysis of mean change in SBP.
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Table 1 Baseline characteristics of all included studies
Study Participants and baseline data Intervention/outcomes
Dapagliflozin
Bailey et al14
Setting: multicentre (n=80)
Design: four-arm, double-blind, placebo-controlled
RCT, dual therapy. Only 10 mg arm included in
NMA
Follow-up: 24 weeks; 102 weeks
N: 534
Participants: patients with type 2 diabetes inadequately
controlled with metformin (≥1500 mg/day)
Age (years): dapa 10 mg+metformin 52.7, SD 9.9;
placebo+metformin 53.7, SD 10.3
HbA1c (%): dapa 10 mg+metformin 7.92, SD 0.82;
placebo+metformin 8.11, SD 0.96
BMI (kg/m2): dapa 10 mg+metformin 31.2, SD 5.1;
placebo+metformin 31.8, SD 5.3
Interventions
10 mg dapa once daily+metformin
Comparator
Placebo+metformin
Outcomes
Primary outcomes: change in HbA1c from baseline to
24 weeks
Other outcomes: change in FPG, change in total body
weight, the proportion of patients achieving an HbA1c
<7% at 24 weeks, change in HbA1c percentage at week
24 for patients with a baseline HbA1c of 9% or more and
percentage change from baseline in bodyweight, and
decreases in bodyweight of 5% or more
Bolinder et al11
Setting: multicentre (n=40) in Bulgaria, Czech
Republic, Hungary, Poland and Sweden
Design: two-arm, double-blind, placebo-controlled
RCT in dual therapy
Duration: 24 weeks
N: 180
Participants: patients with type 2 diabetes inadequately
controlled with metformin (≥1500 mg/day)
Age (years): dapa 10 mg+metformin 60.6, SD 8.2;
placebo+metformin 60.8, SD 6.9
HbA1c (%): dapa 10 mg+metformin 7.19, SD 0.44;
placebo+metformin 7.16, SD 0.53. Note the very low
baseline level
BMI (kg/m2): dapa 10 mg+metformin 32.1, SD 3.9;
placebo+metformin 31.7, SD 3.9
Intervention
10 mg dapa once daily (n=89)+metformin
Comparator
Placebo (n=91)+metformin
Outcomes
Primary outcome: change from baseline at week 24 in
total body weight
Other outcomes: change from baseline at week 24 in
waist circumference, total FM as measured by DEXA;
proportion of patients achieving a body weight reduction
of at least 5% at week 24
Ferrannini et al15
Setting: multicentre (n=85) in the USA, Canada,
Mexico and Russia
Design: double-blind, parallel-group,
placebo-controlled, phase 3 RCT in monotherapy
Duration: 24 weeks
N: 274
Participants: patients with type 2 diabetes mellitus
inadequately controlled with diet and exercise, naïve to
treatment
Age (years): dapa 10 mg 50.6, SD 9.97; placebo 52.7,
SD 10.3
HbA1c (%): dapa 10 mg 8.01, SD 0.96; placebo 7.84,
SD 0.87
BMI (kg/m2): dapa 10 mg+metformin 33.6, SD 5.4;
placebo+metformin 32.3, SD 5.5
Intervention
10 mg dapa (n=70)
Comparator
Placebo (n=75)
Outcomes
Primary outcome: change from baseline in HbA1c at
week 24
Other outcomes: change from baseline at week 24 in
FPG and body weight
Henry et al12
—Two studies (focusing on study 2)
Setting: multicentre (n=131)—hospitals and clinics
in North America, Latin America, Europe and Asia
N: 638
Participants: patients with type 2 diabetes inadequately
controlled with diet and exercise, naïve to treatment
Age (years): dapa 10 mg+metformin 51.5, SD 10.1;
Intervention
10 mg dapa+metformin XR (n=211)
Comparator
Placebo+metformin XR (n=208)
Continued
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Table 1 Continued
Study Participants and baseline data Intervention/outcomes
Design: double-blind, active controlled trials in dual
therapy
Duration: 24 weeks
placebo+metformin 52.7, SD 10.4
HbA1c (%): dapa 10 mg+metformin 9.1, SD 1.3; placebo
+metformin 9.1, SD 1.3
BMI (kg/m2): NR
Outcomes
Primary outcome: change from baseline in HbA1c at
week 24
Secondary/other outcomes: change from baseline at
week 24 in FPG and body weight
Ji et al17
Setting: multicentre (n=40) in China (n=26), Korea
(n=5), Taiwan (n=5) and India (n=4)
Design: double-blind, placebo-controlled,
parallel-group, RCT, monotherapy
Duration: 24 weeks
N: 393
Participants: patients with type 2 diabetes naïve to drug
treatment (prescription medication for diabetes including
Chinese traditional medicines for diabetes, or prescription
medication for diabetes for <24 weeks since diagnosis)
Age (years): dapa 10 mg 51.2, SD 9.89; placebo 49.9,
SD 10.87
HbA1c (%): dapa 10 mg 8.28, SD 0.95; placebo 8.35,
SD 0.95
BMI (kg/m2): dapa 10 mg 25.76, SD 3.43; placebo 25.93,
SD 3.64
Intervention
10 mg dapa (n=133)
Comparator
Placebo (n=132)
Outcomes
Primary outcome: change from baseline in HbA1c at
week 24
Other outcomes: change from baseline in FPG at week
24; change from baseline in 2 h PPG at week 24; change
from baseline in total body weight at week 24; proportion
of patients achieving HbA1c levels of <7% at week 24
Kaku et al23 2014
Setting: multicentre (n=NR) in Japan
Design: double-blind, parallel-group,
placebo-controlled RCT, monotherapy
Duration: 24 weeks
N: 261
Participants: patients with type 2 diabetes naïve to drug
treatment
Age (years): dapa 10 mg 57.5, SD 9.3; placebo 60.4,
SD 9.7
HbA1c (%): dapa 10 mg 7.46, SD 0.61; placebo 7.50,
SD 0.63
BMI (kg/m2): dapa 10 mg 26.6, SD 4.52; placebo 25.22,
SD 4.39
Intervention
10 mg dapa (n=1)
Comparator
Placebo (n=132)
Outcomes
Primary outcome: change from baseline in HbA1c at
week 24
Other outcomes: change from baseline in FPG and body
weight at week 24; change from baseline in total body
weight in patients with baseline BMI of≥25 kg/m2; fasting
insulin and C peptide; seated SBP overall and in patients
with baseline seated SBP≥130 mmHg; fasting lipids;
proportion of patients achieving HbA1c levels of <7% at
week 24 in patients with baseline HbA1c ≥7% and
proportion of patients discontinuing treatment due to lack
of efficacy or rescued for failing to maintain FPG below
prespecified rescue criteria after 24 weeks, and safety
Canagliflozin
Lavalle-Gonzalez et al19
Setting: multicentre (n=169) in 22 countries
Design: double-blind, placebo-controlled and
active-controlled trial, dual therapy
Duration: 26 weeks
N: 1284
Participants: patients with type 2 diabetes inadequately
controlled with metformin
Age (years): cana 100 mg+metformin 55.5, SD 9.4; cana
300 mg+metformin 55.3, SD 9.2; placebo+metformin 55.3,
SD 9.8
Intervention
1. Cana 100 mg+metformin (n=368)
2. Cana 300 mg+metformin (n=367)
Comparator
1. Placebo+metformin (n=186)
Outcomes
Continued
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Table 1 Continued
Study Participants and baseline data Intervention/outcomes
HbA1c (%): cana 100 mg+metformin 7.9, SD 0.9; cana
300 mg+metformin 7.9, SD 0.9; placebo+metformin 8.0,
SD 0.9
BMI (kg/m2): cana 100 mg+metformin 32.4, SD 6.4; cana
300 mg+metformin 31.4, SD 6.3; placebo+metformin 31.1,
SD 6.1
Primary outcome: change in HbA1c from baseline to
week 26
Other outcomes: proportion of patients achieving an
HbA1c level of <7.0%; change in FPG, 2 h PPG and
SBP; change in body weight, triglycerides and HDL-C
Stenlof et al13
Setting: multicentre (n=NR) in 17 countries
Design: double-blind, placebo-controlled, phase 3
RCT, monotherapy
Duration: 26 weeks
N: 584
Participants: patients with type 2 diabetes inadequately
controlled with diet and exercise and also on
antihypoglycaemic agents who underwent washout
(8 weeks and diet and exercise period with placebo run-in
period) of the agent
Age (years): cana 100 mg 55.1, SD 10.8; cana 300 mg
55.3, SD 10.2; placebo 55.7, SD 10.9
HbA1c (%): cana 100 mg 8.1, SD 1.0; cana 300 mg 0,
SD 1.0; placebo 8.0, SD 1.0
BMI (kg/m2): cana 100 mg 31.3, SD 6.6; cana 300 mg
31.7, SD 6.0; placebo 31.8, SD 6.2
Intervention
1. Cana 100 mg (n=195)
2. Cana 300 mg (n=197)
Comparator
1. Placebo (n=192)
Outcomes
Primary outcome: change in HbA1c from baseline to
week 26
Other outcomes: proportion of patients reaching HbA1c
<7.0%; changes from baseline at week 26 in FPG and
SBP; per cent changes from baseline in body weight,
HDL-C and triglycerides
Inagaki et al22
Setting: multicenter (n=31) in Japan
Design: double-blind placebo-controlled phase 3
parallel group trial
Duration: 24 weeks
N: 272
Participants: patients with type 2 diabetes inadequately
controlled with diet and exercise
Age (years): cana 100 mg 58.4, SD 10.4; placebo 58.2,
SD 11.0
HbA1c (%): cana 100 mg 7.98, SD 0.73; placebo 8.04,
SD 0.70
BMI (kg/m2): cana 100 mg 25.59, SD 4.20; placebo 25.85,
SD 4.39
Intervention
1. 100 mg canagliflozin (n=90)
Comparator
1. placebo (n=93)
Outcomes
Primary outcome: change from baseline in HbA1c at
week 24
Other outcomes: proportion of patients achieving HbA1c
target of <7%, change in FPG, PG at 2 h OGTT, per cent
change in body weight, change in waist circumference,
BP, HOMA, per cent change in lipids and safety
Empa
Haring et al16
Setting: multicentre (n=148) in 12 countries
(Canada, China, France, Germany, India, Korea,
Mexico, Slovakia, Slovenia, Taiwan, Turkey and the
USA)
Design: double-blind placebo-controlled phase 3
N: 637
Participants: patients with type 2 diabetes inadequately
controlled with diet and exercise and a stable
immediate-release metformin regimen
Age (years): empa 10 mg+metformin 55.5, SD 9.9; empa
25 mg+metformin 55.6, SD 10.2; placebo+metformin 56,
SD 9.7
Intervention
1. 10 mg empa+metformin (n=217)
2. 25 mg empa+metformin (n=213)
Comparator
1. Placebo+metformin (n=207)
Outcomes
Continued
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Table 1 Continued
Study Participants and baseline data Intervention/outcomes
RCT, dual therapy
Duration: 24 weeks
HbA1c (%): empa 10 mg+metformin 7.94, SD 0.79; empa
25 mg+metformin 7.86, SD 0.87; placebo+metformin 7.90,
SD 0.88
BMI (kg/m2): empa 10 mg+metformin 29.1, SD 5.5; empa
25 mg+metformin 29.7, SD 5.7; placebo+metformin 28.7,
SD 5.2
Primary outcome: change from baseline in HbA1c at
week 24
Other outcomes: change from baseline to week 24 in
body weight and MDG; percentage of patients with
baseline HbA1c ≥7.0% who had HbA1c level <7% at
week 24; change from baseline in FPG, waist
circumference, and SBP and DBP at week 24;
percentage of patients with >5% reduction in body weight
at week 24; use of rescue medication; and safety
Roden et al20
Setting: multicentre (n=124) in 9 countries
(Belgium, Canada, China, Germany, India, Japan,
Switzerland and USA)
Design: double-blind parallel-group RCT,
monotherapy
Duration: 24 weeks
N: 899
Participants: patients with type 2 diabetes with no
previous history to treatment (oral or injected
hypoglycaemic agents 12 weeks prior to randomisation)
Age (years): empa 10 mg 56.2, SD 11.6; empa 25 mg
53.8, SD 11.6; placebo 54.9, SD 10.9
HbA1c (%): empa 10 mg 7.87, SD 0.88; empa 25 mg
7.86, SD 0.85; placebo 7.91, SD 0.87
BMI (kg/m2): empa 10 mg 28.3, SD 5.5; empa 25 mg
28.2, SD 5.5; placebo 28.7, SD 6.2
Intervention
1. 10 mg empa (n=224)
2. 25 mg empa (n=224)
Comparator
1. Placebo (n=228)
Outcomes
Primary outcome: change from baseline in HbA1c at
week 24
Other outcomes: change from baseline in bodyweight at
week 24; change from baseline in SPB and DBP at week
24; proportion of patients with baseline HbA1c level of at
least 7% achieving HbA1c level lower than 7.0% at week
24; change from baseline in FPG at week 24; proportion
of patients with >5% reduction in bodyweight at week 24;
change from baseline in waist circumference at week 24;
proportion of patients with uncontrolled BP at baseline
who controlled their BP at week 24 (SBP <130 mm Hg
and DBP <80 mm Hg); and safety
Luseogliflozin
Seino et al21
Setting: multicentre (n=23) in Japan
Design: double-blind, placebo-controlled,
parallel-group, comparative, RCT, monotherapy
Duration: 24 weeks
N: 158
Participants: patients diagnosed with type 2 diabetes on
stable diet therapy for ≥6 weeks and not on any
antidiabetic drugs
Age (years): luseo 2.5 mg 58.9, SD 10.1; placebo 59.6,
SD 9.3
HbA1c (%): luseo 2.5 mg 8.14, SD 0.91; placebo 8.17,
SD 0.80
BMI (kg/m2): luseo 2.5 mg 25.98, SD 4.88; placebo 25.34,
SD 4.19
Intervention
1. 2.5 mg luseo (n=79)
Comparator
1. Placebo (n=79)
Outcomes
Primary: change in HbA1c from baseline to end of
treatment
Others: plasma glucose, insulin, glucagon, serum CPR,
intact
Ipragliflozin
Kashiwagi et al24
Setting: multicentre (n=34) in Japan
Design: double-blind, placebo-controlled RCT with a
N: 168
Participants: patients with type 2 diabetes of ≥12 weeks
of duration, treated with metformin for ≥6 weeks and with
Intervention
1. Ipra 50 mg+metformin (n=112)
Comparator
Continued
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Table 1 Continued
Study Participants and baseline data Intervention/outcomes
28 weeks open-label extension
Duration: 24 weeks with a 28 weeks open-label
extension
an HbA1c level of 7.4–9.9% and BMI of 20–45 kg/m2
Age (years): ipra 50 mg 56.2, SD 10.67; placebo 57.7, SD
9.24
HbA1c (%): ipra 50 mg 8.25, SD 0.719; placebo 8.38, SD
0.738
BMI (kg/m2): ipra 50 mg 25.96, SD 4.410; placebo 25.47,
SD 3.092
1. Placebo+metformin (n=56)
Outcomes
Primary outcome: change in HbA1c from baseline to end
of treatment
Other outcomes: body weight, waist circumference, FPG,
FSI, plasma leptin, and adiponectin levels, HOMA-R and
HOMA-β and safety outcomes
Togoliflozin
Kaku et al23
Setting: multicentre (n=33) in specialists and
non-specialists hospital in Japan
Design: double-blind, placebo-controlled,
parallel-group RCT
Duration: 24 weeks
N: 235
Participants: patients with type 2 diabetes naïve to drug
therapy but, only treated with diet and exercise for
≥8 weeks before screening, HbA1c level of ≥7.3% to
<10.3%, BMI of ≥18.5 to <45 kg/m2, per cent changes in
HbA1c and body weight from the provisional registration
visit to the final registration visit of ≤10% and <5%,
respectively, controlled BP and those requiring
antihypertensives only those who did not require changing
of their dosing regimen. Patients using other antidiabetic
drugs were eligible if they had stopped their drug
≥8 weeks before the provisional registration. (HbA1c
reported in Japan Diabetes Society or JDS units but,
converted to NGSP units)
Age (years): tofo 10 mg 58.6, SD 9.8; tofo 20 mg 56.6,
SD 10.2; tofo 40 mg 57.0, SD 9.1; placebo 56.8, SD 9.9
HbA1c (%): tofo 10 mg 8.45, SD 0.75; tofo 20 mg 8.34,
SD 0.81; tofo 40 mg 8.37, SD 0.77; placebo 8.41, SD
0.78
BMI (kg/m2): tofo 10 mg 25.07, SD 3.53; tofo 20 mg
24.99, SD 4.55; tofo 40 mg 25.78, SD 4.10; placebo
26.00, SD 4.11
Intervention
1. Tofo 10 mg (n=59)
2. Tofo 20 mg (n=60)
3. Tofo 40 mg (n=59)
Comparator
1. Placebo (n=57)
Outcomes
Primary outcome: change in HbA1c from baseline to end
of treatment
Other outcomes: 24 h FPG, 2 h PPG, fasting and 2 h
postprandial insulin, glycoalbumin, body weight,
pancreatic β-cell function (HOMA-β), insulin resistance
(HOMA-R) and Matsuda index, insulin, serum lipid levels,
adiponectin, BP and waist circumference, and safety
outcomes
BMI, body mass index; cana, canagliflozin; CPR, C peptide immunoreactivity; dapa, dapagliflozin; DBP, diastolic blood pressure; DEXA, dual-energy X-ray absorptiometry; empa, empagliflozin;
FM, fat mass; FPG, fasting plasma glucose; FSI, fasting serum insulin; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-R, homeostasis model assessment of
insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; ipra, ipragliflozin; luseo, luseogliflozin; NMA, network meta-analysis; NR, not reported; OGTT, oral glucose
tolerance test; PPG, postprandial glucose; RCT, randomised controlled trial; SBP, systolic blood pressure; tofo, tofogliflozin.
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Table 2 Summary table with results (monotherapy)
Entry criteria
HbA1c (%)
HbA1c
baseline
Age
baseline
BMI
baseline
Weight
baseline
eGFR
baseline
Per cent
HbA1c
<7%
drug
Per cent
HbA1c
<7%
PBO
Weight
loss
PBO
Weight
loss
drug
Reduction
HA1c PBO
Reduction
HbA1c drug
Difference
HbA1c
Dapagliflozin
Ferrannini et al15 7 to 10 7.84–8.01 50.6–52.7 32.3–33.6 88.8–94.2 NR 51 32 −2.2 −3.2 −0.23 −0.89 −0.66
Ji et al17 ≥7.5 to ≤10.5 8.28–8.35 49.9–51.2 25.76–25.93 70.92–72.18 NR 50 21.3 −0.27 −2.25 −0.29 −1.11 −0.82
Kaku et al23 ≥6.5 to ≤10 7.46–7.50 57.5–60.4 25.22–26.06 65.96–69.7 66.9–67.8 36 19 −0.84 −2.22 −0.06 −0.45 −0.39
Canagliflozin
Inagaki et al22 7 to 10 8.04 58.2–58.4 25.59 to
25.85
68.57–69.10 81.4–84.7 31.5 6.6 −0.76 −3.76 +0.29% −0.74% −1.03%
Stenlof et al13 ≥7.0 to ≤10.0 8.0–8.1 55.1–55.7 31.3–31.8 85.8–87.6 NR 45, 62 21 NR NR 0.14 −0.77;
−1.03
−0.91;
−1.17
Empagliflozin
Roden et al20 ≥7.0 to ≤10.0 7.86–7.91 53.8–56.2 28.2–28.7 77.8–78.4 86.8–87.7 35, 44 12 −0.33 −2.26;
−2.48
0.08 −0.66;
−0.78
−0.74;
−0.86
Luseogliflozin
Seino et al21 ≥6.5 to ≤10.5 8.14–8.17 58.9–59.6 25.34–25.98 66.67–70.19 NR NR NR −0.9 −2.7 +0.13 −0.63 −0.76
Tofogliflozin
Kaku et al23 ≥7.3 to <10.3 8.34–8.45 56.6–58.6 24.99–26 67.26–71.20 83.78–86.78 NR NR −0.356 −2.23
−2.851
−2.971
−0.028 −0.767
−1.017
−0.870
−0.769
−0.990
−0.842
HbA1c in per cent; age in years; BMI in kg/m2; weight in kg; eGFR in mL/min/1.73 m2.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; NR, not reported; PBO, placebo.
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All SGLT-2 inhibitors were signiﬁcantly more effective
than placebo for achieving HbA1c <7% (ﬁgure 9), redu-
cing HbA1c (%) from baseline (ﬁgure 10), weight loss
(ﬁgure 11) and reducing SBP (ﬁgure 12). The results
were slightly different when the trials by Kashiwagi et al24
and Henry et al12 were included, as discussed later.
Empagliﬂozin 25 and 10 mg, and canagliﬂozin 300 mg
had higher proportions of patients achieving HbA1c
<7% than canagliﬂozin 100 mg and dapagliﬂozin 10 mg
(ﬁgure 9).
Canagliﬂozin 300 mg gave the greatest reduction in
HbA1c (0.77%), but the differences were small (vs cana-
gliﬂozin 100 mg (MD=0.15, 95% CrI 0.04 to 0.26) and
dapagliﬂozin 10 mg (MD=0.23, 95% CrI −0.01 to 0.47);
ﬁgure 10). There were no statistically signiﬁcant differ-
ences between the two doses of canagliﬂozin and the
two doses of empagliﬂozin.
In sensitivity analyses compared with placebo (ﬁgure
13), ipragliﬂozin 50 mg showed the greatest reduction in
HbA1c (1.25%) followed by canagliﬂozin 300 mg
(0.77%), empagliﬂozin 25 mg (0.64%), canagliﬂozin
100 mg (0.62%), empagliﬂozin 10 mg (0.57%) and
dapagliﬂozin 10 mg (0.54%), but as noted above, we
have reservations about the Kashiwagi study.
All the drugs were associated with greater weight loss
than placebo, ranging from a reduction of 1.63 kg on
empagliﬂozin 10 mg to 2.5 kg on canagliﬂozin 300 mg
(ﬁgure 11). Canagliﬂozin 300 mg was statistically signiﬁ-
cantly better in reducing weight than empagliﬂozin
10 mg (MD 0.88 kg, 95% CrI 0.16 to 1.61) and ipragliﬂo-
zin 50 mg (0.81 kg, 95% CrI 0.03 to 1.58; ﬁgure 14).
For mean change in SBP, inclusion of the Kashiwagi
(ipragliﬂozin) and Henry studies (dapagliﬂozin) caused
contrasting results. By excluding them, all ﬂozins (cana-
gliﬂozin 300 and 100 mg, empagliﬂozin 25 and 10 mg)
were associated with signiﬁcant reduction in SBP com-
pared with placebo, but there were no signiﬁcant differ-
ences among them (ﬁgure 12). By including the two
studies, all ﬂozins including dapagliﬂozin and ipragliﬂo-
zin were found to be signiﬁcantly better than placebo,
but less so than without them, and there were differ-
ences between them. Dapagliﬂozin 10 mg was found to
be signiﬁcantly better than all other ﬂozins, and ipragli-
ﬂozin 50 mg, canagliﬂozin 300 mg and empagliﬂozin
25 mg were found to be better than empagliﬂozin 10 mg
(ﬁgure 15).
For some comparisons, between-study variance was
small suggesting no heterogeneity; however, the CrIs
were wide which reﬂects the small number of studies
available for pairwise comparisons. Analyses based on
direct versus indirect comparisons showed no evidence
of inconsistency between direct and indirect evidence in
the network for all outcomes.
The effect of including the Bolinder trial was that the
mean reduction in HbA1c on dapagliﬂozin became sig-
niﬁcantly less than with canagliﬂozin 300 mg, empagli-
ﬂozin 25 mg and canagliﬂozin 100 mg. The ﬁndings for
weight did not change. However, as noted earlier,
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patients in the Bolinder trial started at a much lower
baseline HbA1c and had a much smaller mean reduc-
tion in HbA1c.
A sensitivity analysis including the Henry and
Kashiwagi trials is shown in ﬁgure 16. The CIs around
ipragliﬂozin are very wide because no patients in the
placebo group achieved HbA1c under 7%.
DISCUSSION
Statement of principal findings
Our NMA showed few differences among the ﬂozins. In
monotherapy, canagliﬂozin 300 mg gave the largest
reduction in HbA1c among the SGLT-2 inhibitors in
patients with type 2 diabetes with inadequate glycaemic
control on diet and exercise alone. However, treatment
with canagliﬂozin would be started with 100 mg and
only increased in those with an insufﬁcient response to
that dose. Those with a poor response to the 100 mg
dose might also have a poor response to 300 mg.
In monotherapy, the reduction in weight was greatest
with canagliﬂozin 100 mg (−3 kg). All the SGLT-2 inhibi-
tors reduced SBP, though wide CIs meant that differ-
ences were not always statistically signiﬁcant. In dual
therapy with metformin, canagliﬂozin 300 mg gave the
greatest reductions in HbA1c (0.77%) and weight
(−2.5 kg), and these differences were sometimes statistic-
ally signiﬁcant but not clinically so. There were no statis-
tically signiﬁcant differences among the drugs in
reducing SBP.
Strengths and limitations
We compared the efﬁcacy of SGLT-2 inhibitors in patients
with type 2 diabetes inadequately controlled with diet
and exercise or metformin monotherapy. The relevant
studies were identiﬁed systematically. Data extraction and
Figure 2 Network plot—monotherapy (mean change in
glygated haemoglobin).
Figure 3 Network plot—dual
therapy (% of patients achieving
glycated haemoglobin <7%).
Figure 4 Risk of bias.
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quality assessment of the included studies were checked
systematically by two authors. Most of the included
studies were high in quality but the risk of bias in some
studies could not be judged due to lack of information.
Our study has strengths. Unlike conventional pair wise
meta-analysis, our NMAs allow for comparisons between
SGLT-2 inhibitors that have not been compared
head-to-head in RCTs. In addition, combining direct
and indirect evidence in NMA offer additional precision
by ‘borrowing strength’ from indirect evidence.25
Another strength of the NMA is that it treats all com-
parators as separate treatments while gaining statistical
power from including all available data.26
The main limitation is the lack of head-to-head trials.
The number of trials contributing evidence to several
comparisons in the network was small.
Figure 5 Proportion of patients achieving HbA1c level of <7%—monotherapy. HbA1c, glycated haemoglobin; NA, not available;
NMA, network meta-analysis.
Figure 6 Mean change in HbA1c (%)—monotherapy. HbA1c, glycated haemoglobin; NA, not available; NMA, network
meta-analysis.
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Another limitation is that in the trials, patients were
randomised to canagliﬂozin 300 mg, whereas in clinical
practice, they would be tried on 100 mg daily ﬁrst.
One of the three dapagliﬂozin trials, by Kaku et al,18
recruited patients with a baseline HbA1c of only 7.5%,
and not surprisingly their reduction in HbA1c was less
(0.39%) than in most other trials. Exclusion of this study
would raise the mean reduction on dapagliﬂozin to
0.75% (Astra Zeneca corporate communication, at NICE
Appraisal Committee 25 November 2015).
Another factor to be considered is that in the dapagli-
ﬂozin trials, HbA1c fell in the placebo groups, by 0.29%
and 0.23% in the Ji et al17 and Ferrannini et al15 trials. In
the Ferrannini trial, weight fell signiﬁcantly by 2.2 kg. In
Figure 7 Mean change in weight (kg)—monotherapy. NA, not available; NMA, network meta-analysis.
Figure 8 Mean change in SBP (mm Hg)—monotherapy. NA, not available; NMA, network meta-analysis; SBP, systolic blood
pressure.
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the placebo groups in the canagliﬂozin trials, HbA1c rose
by 0.29%22 and 0.14% (Stenlof CANTATA-M).13
Ferranini et al suggested that the reduction in HbA1c in
the placebo group might have been due to improved
adherence to lifestyle advice in that group, but since the
placebo tablets matched the dapagliﬂozin ones, this
seems unlikely.
When interpreting weight changes, the baseline body
mass indices (BMIs) need to be considered. The trials
in China and Japan recruited people with BMIs in the
25–26 range, whereas the European trials had mean
BMIs ranging from 28 to almost 34.
Some of the included studies did not report data on
all outcomes, and for these, we were not able to
Figure 9 Proportion of patients achieving HbA1c level of <7.0%—dual therapy. HbA1c, glycated haemoglobin; NA, not
available; NMA, network meta-analysis.
Figure 10 Mean change in HbA1c (%)—dual therapy. HbA1c, glycated haemoglobin; NA, not available; NMA, network
meta-analysis.
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compare all the SGLT-2 inhibitors against each other.
For example, the Seino et al21 trial with the new SGLT-2
inhibitor, luseogliﬂozin, did not provide data on propor-
tion of patients achieving HbA1c level of <7% and mean
change in SBP.
The primary outcomes of both canagliﬂozin studies
were reported at 26 weeks instead of 24 weeks.
Therefore, we assumed that the effect of canagliﬂozin
measured at 26 weeks was comparable against other
SGLT-2 inhibitors, which reported results at 24 weeks.
The numbers of patients in each centre were often
small, such as means of 3.2 patients per centre in the
Ferranini trial and 4.5 in the Bolinder one. This must
raise questions about how typical the recruits were. We
did not compare safety data.
Meaning of the study
In the absence of head-to-head comparison of SGLT-2
inhibitors in patients with type 2 diabetes inadequately
controlled with diet and exercise or metformin, this
Figure 11 Mean change in weight (kg)—dual therapy. NA, not available; NMA, network meta-analysis.
Figure 12 Mean change in SBP (mm Hg)—dual therapy. NA, not available; NMA, network meta-analysis; SBP, systolic blood
pressure.
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study examines the evidence as to whether any drug is
better than others. NICE has approved dapagliﬂozin
10 mg as an option for the treatment of diabetes in com-
bination with metformin or as an add-on to insulin with
or without other glucose-lowering drugs.1 NICE has
approved canagliﬂozin as dual therapy (in combination
with metformin if sulfonylurea is contraindicated) or
triple therapy (in combination with metformin plus sul-
fonylurea or metformin plus thiazolidinediones) or as
add on to insulin with or without other antidiabetic
drugs.2 Empagliﬂozin has also been approved by NICE
in combination therapy.3
The usual ﬁrst drug for type 2 diabetes is metformin,
with sulfonylurea in those who cannot tolerate
Figure 13 Proportion of patients achieving HbA1c level of <7.0% (dual therapy), sensitivity analysis including Henry et al12 and
Kashiwagi et al.24 HbA1c, glycated haemoglobin; NA, not available; NMA, network meta-analysis.
Figure 14 Mean change in weight (kg; dual therapy), sensitivity analysis including Bolinder et al,11 Henry et al12 2012 and
Kashiwagi et al.24 NA, not available; NMA, network meta-analysis.
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metformin. NICE is appraising the use of the ﬂozins in
monotherapy in people who cannot take metformin in
2015.27 It has been pointed out that the ﬂozins are the
only oral glucose-lowering drugs that are associated with
weight reduction.
A recent mixed treatment comparison, available in
abstract only at present,28 compared the efﬁcacy and
safety of canagliﬂozin in dual therapy (in combination
with metformin) using a Bayesian approach against sul-
fonylureas, pioglitazone, dipeptidyl peptidase-4 (DPP-4)
inhibitors, glucagon-like peptide-1 (GLP-1) analogues
and dapagliﬂozin. The outcomes compared were
HbA1c, weight and hypoglycaemia at 26, 52 and
104 weeks. Pacou et al reported that both canagliﬂozin
100 and 300 mg led to larger reductions in HbA1c level
than with DPP-4 inhibitors and dapagliﬂozin but similar
Figure 15 Mean change in SBP (mm Hg; dual therapy), sensitivity analysis including Kashiwagi et al.24 NA, not available; NMA,
network meta-analysis; SBP, systolic blood pressure.
Figure 16 Mean change in HbA1c (%; dual therapy), sensitivity analysis including Bolinder et al,11 Henry et al12 and Kashiwagi
et al.24 HbA1c, glycated haemoglobin; NA, not available; NMA, network meta-analysis.
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reduction in HbA1c to liraglutide over 104 weeks. The
weight reduction was also comparable to GLP-1 analo-
gues. Hypoglycaemia was less frequent with all SGLT-2
inhibitors compared with sulfonylureas. The mixed treat-
ment comparison undertaken by Pacou et al (most of
whom are associated with Janssen, the manufacturers of
canagliﬂozin) was not available in full, so we were not
able to determine which studies were included or to
assess the quality of the study.
Our initial question was whether canagliﬂozin is more
potent than other SGLT-2 inhibitors, due to its dual
effect on SGLT-2 and SGLT-1 receptors. In monotherapy,
both doses of canagliﬂozin lowered HbA1c slightly more
than both doses of empagliﬂozin, which does not have
signiﬁcant effects on SGLT-1 receptors. These differ-
ences were not seen in dual therapy. This suggests that
the SGLT-1 effect may not be clinically signiﬁcant.
There are still unanswered questions. We do not know
how long SGLT-2 inhibitors would be effective for, but as
the mode of action is independent of insulin release,
one might expect them to be effective irrespective of
diabetes duration. Women taking these drugs have
increases in urinary tract and genital tract infection but
these are reported in the trials to be mild in intensity. At
present, we do not know if there are long-term adverse
effects, either from the class as a whole or from individ-
ual drugs. There has been recent concern about dia-
betic ketoacidosis among people on the SGLT-2
inhibitors.29 30
CONCLUSION
There are few clinically signiﬁcant differences among
the drugs. In monotherapy, reductions in HbA1c were
largest with canagliﬂozin and smallest with dapagliﬂozin.
Differences in HbA1c were insigniﬁcant in dual therapy.
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